NEWARK, CA -- (Marketwired) -- 02/03/14 -- CymaBay (OTCQB: CYMA) announced that Harold Van Wart, CEO will be presenting at the 16th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.
About the BIO CEO & Investor Conference
The 16th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2013 CEO & Investor Conference featured 1,380 partnering meetings, 148 company presentations, and 1,400 attendees, over half of which were investors.
For additional information about CymaBay visit www.cymabay.com.
Source: CymaBay Therapeutics